<unk>  is used as a form of high-dose estrogen therapy in the treatment of castration-resistant prostate cancer. It is added once progression of metastases has occurred following therapy with other interventions such orchiectomy, gonadotropin-releasing hormone modulators, and nonsteroidal antiandrogens.<unk>  has also been used to prevent the testosterone flare at the start of gonadotropin-releasing hormone agonist therapy in men with prostate cancer.<unk>  sodium is given at a dosage of 600 to 1200 mg/day by slow intravenous infusion over a period of 1 hour for a treatment duration of 5 to 10 days in men with prostate cancer. Following this, it is given at a dose of 300 mg/day for 10 to 20 days. Maintenance doses of<unk>  sodium of 300 to 600 mg may be given four times per week. This may be gradually reduced to one 300 to 600-mg dose per week over a period of several months.<unk>  sodium is also used to a lesser extent by oral administration initially at a dosage of 360 to 480 mg three times per day in the treatment of prostate cancer. Maintenance doses of 120 to 240 mg three times per day may be used and can be gradually reduced to 240 mg/day. Available forms<unk>  is available in the form of solutions for intravenous administration and tablets for oral administration.
Fosfestrol
Hexestrol
Gestodene
Benzestrol
Moxestrol
Dienestrol
Dimestrol
Goserelin